Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report released on Wednesday. The brokerage set a “hold” rating on the stock.

Can-Fite BioPharma Trading Down 1.9 %

Shares of NYSE:CANF opened at $2.07 on Wednesday. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $3.33. The stock’s 50-day moving average price is $2.15 and its two-hundred day moving average price is $2.10. The firm has a market cap of $7.33 million, a price-to-earnings ratio of -1.16 and a beta of 1.58.

Can-Fite BioPharma (NYSE:CANF) last released its earnings results on Thursday, March 28th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. The company had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.20 million. As a group, research analysts forecast that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Armistice Capital LLC acquired a new position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 154,363 shares of the company’s stock, valued at approximately $340,000. Armistice Capital LLC owned 4.36% of Can-Fite BioPharma as of its most recent SEC filing. Hedge funds and other institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.